General MedicationsORALGeneric

DYNACIRC CR

ISRADIPINE

Standard Dose

5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

Max Dose

Refer to approved labeling

Primary Use

Review priority: STANDARD Marketing status: Discontinued

Summary

Approval overview DYNACIRC CR is listed in Drugs@FDA under application 020336 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient ISRADIPINE Form and strength TABLET, EXTENDED RELEASE;ORAL - 5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor GLAXOSMITHKLINE LLC Submission history Latest submission status date: 2005-05-18 00:00:00.

Structured Monograph

Clinical summary

Approval overview DYNACIRC CR is listed in Drugs@FDA under application 020336 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient ISRADIPINE Form and strength TABLET, EXTENDED RELEASE;ORAL - 5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor GLAXOSMITHKLINE LLC Submission history Latest submission status date: 2005-05-18 00:00:00. Submission type: SUPPL.

Monitoring

• Marketing status: Discontinued
• Review priority: STANDARD

Interaction Notes

No interaction notes stored yet.